Search Results - "Barneto, Isidoro"

Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial by Provencio, Mariano, Nadal, Ernest, Insa, Amelia, García-Campelo, María Rosario, Casal-Rubio, Joaquín, Dómine, Manuel, Majem, Margarita, Rodríguez-Abreu, Delvys, Martínez-Martí, Alex, De Castro Carpeño, Javier, Cobo, Manuel, López Vivanco, Guillermo, Del Barco, Edel, Bernabé Caro, Reyes, Viñolas, Nuria, Barneto Aranda, Isidoro, Viteri, Santiago, Pereira, Eva, Royuela, Ana, Casarrubios, Marta, Salas Antón, Clara, Parra, Edwin R, Wistuba, Ignacio, Calvo, Virginia, Laza-Briviesca, Raquel, Romero, Atocha, Massuti, Bartomeu, Cruz-Bermúdez, Alberto

“…Non-small-cell lung cancer (NSCLC) is terminal in most patients with locally advanced stage disease. We aimed to assess the antitumour activity and safety of…”
Get full text

Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression by Rosell, Rafael, Perez-Roca, Laia, Sanchez, Jose Javier, Cobo, Manuel, Moran, Teresa, Chaib, Imane, Provencio, Mariano, Domine, Manuel, Sala, Maria Angeles, Jimenez, Ulpiano, Diz, Pilar, Barneto, Isidoro, Macias, Jose Antonio, de Las Peñas, Ramon, Catot, Silvia, Isla, Dolores, Sanchez, Jose Miguel, Ibeas, Rafael, Lopez-Vivanco, Guillermo, Oramas, Juana, Mendez, Pedro, Reguart, Noemi, Blanco, Remei, Taron, Miquel

“…Median survival is 10 months and 2-year survival is 20% in metastatic non-small-cell lung cancer (NSCLC) treated with platinum-based chemotherapy. A small…”
Get full text

Patient preference for oral chemotherapy in the treatment of metastatic breast and lung cancer by Ciruelos, Eva María, Díaz, María Nieves, Isla, María Dolores, López, Rafael, Bernabé, Reyes, González, Encarnación, Cirauqui, Beatriz, Coves, Juan, Morales, Serafín, Arcediano, Alberto, Barneto, Isidoro, Cerezuela, Pablo, Illarramendi, José Juan, Morales, Cristina, Ponce, Santiago

“…Objectives Although new therapies against metastatic cancer have been developed in recent decades, chemotherapy is still an important treatment option…”
Get full text

Neoadjuvant chemo-immunotherapy for the treatment of stage IIIA resectable non-small-cell lung cancer (NSCLC): A phase II multicenter exploratory study—Final data of patients who underwent surgical assessment by Provencio, Mariano, Nadal, Ernest, Insa, Amelia, Garcia-Campelo, Rosario, Casal Rubio, Joaquín, Domine, Manuel, Majem, Margarita, Rodriguez-Abreu, Delvys, Martinez Marti, Alex, Cobo, Manuel, Lopez-Vivanco, Guillermo, del Barco, Elvira, Bernabé, Reyes, Vinolas, Nuria, Barneto, Isidoro, Viteri, Santiago, Martín-Martorell, Paloma, Jove, Maria, Franco, Fabio, Massuti, Bartomeu

“…Abstract only 8509 Background: Patients with stage IIIA (N2 or T4N0) are potentially curable but median overall survival is only around 15 months and complete…”
Get full text

Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy by Casarrubios, Marta, Cruz-Bermúdez, Alberto, Nadal, Ernest, Insa, Amelia, García Campelo, María Del Rosario, Lázaro, Martín, Dómine, Manuel, Majem, Margarita, Rodríguez-Abreu, Delvys, Martínez-Martí, Alex, de Castro-Carpeño, Javier, Cobo, Manuel, López-Vivanco, Guillermo, Del Barco, Edel, Bernabé Caro, Reyes, Viñolas, Nuria, Barneto Aranda, Isidoro, Viteri, Santiago, Massuti, Bartomeu, Barquín, Miguel, Laza-Briviesca, Raquel, Sierra-Rodero, Belén, Parra, Edwin R, Sanchez-Espiridion, Beatriz, Rocha, Pedro, Kadara, Humam, Wistuba, Ignacio I, Romero, Atocha, Calvo, Virginia, Provencio, Mariano

“…Characterization of the T-cell receptor (TCR) repertoire may be a promising source for predictive biomarkers of pathologic response to immunotherapy in locally…”
Get full text

Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain by Arriola, Edurne, García Gómez, Ramón, Diz, Pilar, Majem, Margarita, Martínez Aguillo, Maite, Valdivia, Javier, Paredes, Alfredo, Sánchez-Torres, José Miguel, Peralta Muñoz, Sergio, Barneto, Isidoro, Gutierrez, Vanesa, Andrade Santiago, Jesús Manuel, Aparisi, Francisco, Isla, Dolores, Ponce, Santiago, Vicente Baz, David, Artal, Angel, Amador, Mariluz, Provencio, Mariano

“…Although the benefit of first-line epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors (TKIs) over chemotherapy has been demonstrated in several…”
Get full text

Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC – The ETOP/EORTC SPLENDOUR and AMGEN-249 trials by Peters, Solange, Danson, Sarah, Ejedepang, Dunson, Dafni, Urania, Hasan, Baktiar, Radcliffe, Hoi-Shen, Bustin, Frederique, Crequit, Jacky, Coate, Linda, Guillot, Monica, Surmont, Veerle, Rauch, Daniel, Rudzki, Jakob, O'Mahony, Deirdre, Barneto Aranda, Isidoro, Scherz, Amina, Tsourti, Zoi, Roschitzki-Voser, Heidi, Pochesci, Alessia, Demonty, Gaston, Stahel, Rolf A., O'Brien, Mary

“…•SPLENDOUR and AMGEN-249 tested denosumab and chemotherapy in advanced NSCLC.•The pooled analysis aims to conclude about the impact of denosumab in NSCLC.•The…”
Get full text

Randomized Phase III Study of Gemcitabine-Cisplatin Versus Etoposide-Cisplatin in the Treatment of Locally Advanced or Metastatic Non–Small-Cell Lung Cancer by Cardenal, F, López-Cabrerizo, M P, Antón, A, Alberola, V, Massuti, B, Carrato, A, Barneto, I, Lomas, M, García, M, Lianes, P, Montalar, J, Vadell, C, González-Larriba, J L, Nguyen, B, Artal, A, Rosell, R

“…We conducted a randomized trial to compare gemcitabine-cisplatin with etoposide-cisplatin in the treatment of patients with advanced non-small-cell lung cancer…”
Get full text

Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy by Casarrubios, Marta, Provencio, Mariano, Nadal, Ernest, Insa, Amelia, del Rosario García-Campelo, María, Lázaro-Quintela, Martín, Dómine, Manuel, Majem, Margarita, Rodriguez-Abreu, Delvys, Martinez-Marti, Alex, De Castro Carpeño, Javier, Cobo, Manuel, López Vivanco, Guillermo, Del Barco, Edel, Bernabé, Reyes, Viñolas, Nuria, Barneto Aranda, Isidoro, Massuti, Bartomeu, Sierra-Rodero, Belén, Martinez-Toledo, Cristina, Fernández-Miranda, Ismael, Serna-Blanco, Roberto, Romero, Atocha, Calvo, Virginia, Cruz-Bermúdez, Alberto

“…BackgroundNeoadjuvant chemoimmunotherapy for non-small cell lung cancer (NSCLC) has improved pathological responses and survival rates compared with…”
Get full text

Perioperative chemoimmunotherapy induces strong immune responses and long-term survival in patients with HLA class I-deficient non-small cell lung cancer by Molina-Alejandre, Marta, Perea, Francisco, Calvo, Virginia, Martinez-Toledo, Cristina, Nadal, Ernest, Sierra-Rodero, Belén, Casarrubios, Marta, Casal-Rubio, Joaquín, Martinez-Martí, Alex, Insa, Amelia, Massuti, Bartomeu, Viteri, Santiago, Barneto Aranda, Isidoro, Rodriguez-Abreu, Delvys, de Castro, Javier, Martínez, Joaquín Mosquera, Cobo, Manuel, Wistuba, Ignacio I, Parra, Edwin R, Martín-López, Javier, Megías, Diego, Muñoz-Viana, Rafael, Garrido, Federico, Aptsiauri, Natalia, Ruiz-Cabello, Francisco, Provencio, Mariano, Cruz-Bermúdez, Alberto

“…BackgroundLoss of human leukocyte antigen (HLA) class I expression and loss of heterozygosity (LOH) are common events implicated in the primary resistance of…”
Get full text

Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial by Sierra-Rodero, Belén, Cruz-Bermúdez, Alberto, Nadal, Ernest, Garitaonaindía, Yago, Insa, Amelia, Mosquera, Joaquín, Casal-Rubio, Joaquín, Dómine, Manuel, Majem, Margarita, Rodriguez-Abreu, Delvys, Martinez-Marti, Alex, De Castro Carpeño, Javier, Cobo, Manuel, López Vivanco, Guillermo, Del Barco, Edel, Bernabé Caro, Reyes, Viñolas, Nuria, Barneto Aranda, Isidoro, Viteri, Santiago, Massuti, Bartomeu, Laza-Briviesca, Raquel, Casarrubios, Marta, García-Grande, Aránzazu, Romero, Atocha, Franco, Fernando, Provencio, Mariano

“…BackgroundPneumonitis (Pn) is one of the main immune-related adverse effects, having a special importance in lung cancer, since they share affected tissue…”
Get full text

Perioperative Nivolumab and Chemotherapy in Stage III Non–Small-Cell Lung Cancer by Provencio, Mariano, Nadal, Ernest, González-Larriba, José L., Martínez-Martí, Alex, Bernabé, Reyes, Bosch-Barrera, Joaquim, Casal-Rubio, Joaquín, Calvo, Virginia, Insa, Amelia, Ponce, Santiago, Reguart, Noemí, de Castro, Javier, Mosquera, Joaquín, Cobo, Manuel, Aguilar, Andrés, López Vivanco, Guillermo, Camps, Carlos, López-Castro, Rafael, Morán, Teresa, Barneto, Isidoro, Rodríguez-Abreu, Delvys, Serna-Blasco, Roberto, Benítez, Raquel, Aguado de la Rosa, Carlos, Palmero, Ramón, Hernando-Trancho, Florentino, Martín-López, Javier, Cruz-Bermúdez, Alberto, Massuti, Bartomeu, Romero, Atocha

“…In patients with lung cancer, neoadjuvant treatment with nivolumab and chemotherapy resulted in a significantly higher percentage of patients with a…”
Get full text

Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial by Aix, Santiago Ponce, Ciuleanu, Tudor Eliade, Navarro, Alejandro, Cousin, Sophie, Bonanno, Laura, Smit, Egbert F, Chiappori, Alberto, Olmedo, Maria Eugenia, Horvath, Ildiko, Grohé, Christian, Farago, Anna F, López-Vilariño, José Antonio, Cullell-Young, Martin, Nieto, Antonio, Vasco, Noelia, Gómez, Javier, Kahatt, Carmen, Zeaiter, Ali, Carcereny, Enric, Roubec, Jaromir, Syrigos, Konstantinos, Lo, Gregory, Barneto, Isidoro, Pope, Anthony, Sánchez, Amparo, Kattan, Joseph, Zarogoulidis, Konstantinos, Waller, Cornelius F, Bischoff, Helge, Juan-Vidal, Oscar, Reinmuth, Niels, Dómine, Manuel, Paz-Ares, Luis

“…Lurbinectedin is a synthetic marine-derived anticancer agent that acts as a selective inhibitor of oncogenic transcription. Lurbinectedin monotherapy (3·2…”
Get full text

METASNCore: A new tool for palliative whole brain radiotherapy (WBRT) assessment in the era of targeted therapies by Flores Paco, Pablo, Vargas, Alicia, Guevara, Maria Geraldina, Lopera, Ignacio, Rodríguez Ruiz, Lucía, María, López-Herrero, Camús, Juan Adrián, López-González, Javier, Inga-Saavedra, Elizabeth, Montero, Marina, Barneto, Isidoro, Gomez, Maria Auxiliadora, Ruiz, Estela, Ruza, Marta, Tudela, María Luz, Palacios, Amalia, De La Haba, Juan, Aranda, Enrique

“…e24154 Background: Palliative WBRT has been the main treatment for multiple brain metastases (BM). Recent studies report no benefit in survival or quality of…”
Get full text

Association of peripheral memory B cell population maintenance and long term survival after perioperative chemoimmunotherapy in NSCLC (NADIM trial) by Sierra-Rodero, Belen, Cruz Bermudez, Alberto, Martinez-Toledo, Cristina, Molina-Alejandre, Marta, García-Grande, Aránzazu, Calvo, Virginia, Nadal, Ernest, Campelo, Rosario Garcia, Insa, Amelia, Domine, Manuel, Massuti, Bartomeu, Garrido, Alberto, Majem, Margarita, Martinez-Marti, Alex, de Castro Carpeño, Javier, Rodriguez-Abreu, Delvys, Cobo, Manuel, Barneto, Isidoro, Viteri, Santiago, Provencio-Pulla, Mariano

“…8551 Background: In the context of perioperative immunotherapy, it is crucial to personalize adjuvant treatment, identifying which patients should or should…”
Get full text

A new updated prognostic index for patients with brain metastases (BMs) treated with palliative whole brain radiotherapy (WBRT) in the era of precision oncology. METASNCore project by Flores-Paco, Pablo, Vargas-Aliaga, Alicia, Guevara, María Geraldina, Lopera, Ignacio, Ruiz, Lucía Rodríguez, López-Herrero, María, Camús, Juan Adrián, López-González, Javier, Inga-Saavedra, Elizabeth, Montero, Marina, Barneto, Isidoro, Gómez-España, Mª Auxiliadora, Ruiz, Estela, Ruza, Marta, Armenta, Ana, Palacios, Amalia, De La Haba-Rodríguez, Juan R., Aranda, Enrique

“…Introduction Palliative WBRT is the main treatment for multiple BMs. Recent studies report no benefit in survival after WBRT compared to palliative supportive…”
Get full text

Multimodal prediction of response to neoadjuvant nivolumab and chemotherapy for surgically resectable stage IIIA non–small cell lung cancer by Ferrer, Loïc, Nadal, Ernest, Guidel, Floriane, Insa, Amelia, Menu, Philippe, Casal, Joaquin, Domine, Manuel, Massuti, Bartomeu, Majem, Margarita, Martinez-Marti, Alex, Campelo, Rosario Garcia, de Castro Carpeño, Javier, Cobo, Manuel, Lopez Vivanco, Guillermo, del Barco, Edel, Bernabé, Reyes, Vinolas, Nuria, Barneto, Isidoro, Colin, Thierry, Provencio-Pulla, Mariano

“…8542 Background: The NADIM trial (NCT03081689), led by the Spanish Lung Cancer Group, assessed the antitumor activity and safety of neoadjuvant…”
Get full text

BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC by Provencio, Mariano, Robado de Lope, Lucía, Serna-Blasco, Roberto, Nadal, Ernest, Diz Tain, Pilar, Massuti, Bartomeu, González-Larriba, José Luis, Insa, Amelia, Sánchez-Hernández, Alfredo, Casal-Rubio, Joaquín, García-Campelo, Rosario, Sequero López, Silvia, Rogado, Jacobo, Martínez-Martí, Alex, Bosch-Barrera, Joaquim, Bernabé, Reyes, Vázquez Estévez, Sergio, Ponce, Santiago, de Castro, Javier, Coves Sarto, Juan, Reguart, Noemí, Dómine, Manuel, Aguilar, Andrés, Majem, Margarita, Estival, Anna, Peña Cabia, Silvia, López Martín, Ana, Sala González, María Ángeles, Cobo, Manuel, Camps, Carlos, Barneto, Isidoro, Calvo, Virginia, Collazo-Lorduy, Ana, Cruz-Bermúdez, Alberto, Romero, Atocha

“…•Efficacy of ICIs in NSCLC patients with BRAF mutations remains uncertain.•Our data showed an increased pathological complete response rate in BRAF-mutant…”
Get full text

Abstract 560: High levels of baseline ctDNA constitute a poor prognostic factor in progression-free survival in patients receiving neo-adjuvant chemo-immunotherapy: Results from NADIM clinical trial by Provencio, Mariano, Serna-Blasco, Roberto, Nadal, Ernest, Insa, Amelia, Garcia-Campelo, M. Rosario, Corbacho, Diego Pereiro, Domine, Manuel, Majem, Margarita, Rodriguez-Abreu, Delvys, Martinez-Marti, Alex, de Castro, Javier, Cobo, Manuel, Lopez-Vivanco, Guillermo, del Barco, Edel, Bernabe, Reyes, Viñolas, Nuria, Barneto, Isidoro, Viteri, Santiago, Pereira, Eva, Royuela, Ana, Casarrubios, Marta, Salas, Clara, Parra, Edwin R, Wistuba, Ignacio, Calvo, Virginia, Laza-Briviesca, Raquel, Massuti, Bartomeu, Cruz-Vermudez, Alberto, Romero, Atocha

“…Abstract There is growing evidence supporting that long-term survival of neoadjuvant chemo-immunotherapy for locally advanced NSCLC patients can be achieved…”
Get full text

Haematological biomarkers of pathological response on neo-adjuvant chemo-immunotherapy treatment for resectable stage IIIA non-small cell lung cancer (NSCLC) patients by Laza Briviesca, Raquel, Cruz Bermudez, Alberto, Barquin, Miguel, Nadal, Ernest, Insa, Amelia, Garcia-Campelo, Rosario, De Dios Alvarez, Noemi, Domine, Manuel, Massuti, Bartomeu, Majem, Margarita, Rodriguez-Abreu, Delvys, Martinez Marti, Alex, Cobo, Manuel, Lopez-Vivanco, Guillermo, del Barco, Elvira, Bernabé, Reyes, Vinolas, Nuria, Barneto, Isidoro, Viteri, Santiago, Provencio-Pulla, Mariano

“…Abstract only e20026 Background: PD1/PDL1 treatments have become the main therapy in advanced stages of NSCLC due to its significant increase in overall…”
Get full text